- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses Management of Pediatric Type 1, 2 Diabetes
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses some of the challenges of treating pediatric patients with type 1 or type 2 diabetes.
The American Diabetes Association (ADA) recognizes that type 2 diabetes in young people is a more severe disease, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the ADA.
Transcript
Section 14 of the ADA's 2022 Standards of Medical Care in Diabetes added new information about pediatric type 1 and type 2 diabetes. What is lacking in the care for children?
We recognize that particularly type 2 diabetes in young people is a more severe disease. It progresses more rapidly, and the risk of complications is higher. It's, in essence, a more aggressive disease, and so it's important that clinicians think about how to best manage those individuals and also to screen for them.
Young people with type 1 diabetes continue to be a challenging group and particularly young adults where, if anything, A1C [glycated hemoglobin], not only has it not gotten any better for that population, but it has gotten worse despite all of the technology that's become available. So it was important for us to emphasize the best management about type 1 and type 2 diabetes in children.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
